CapeHaven, a biotech venture creation platform based in New Haven, has announced the first close of a funding round targeting $10 million. The investment, sourced from individual and institutional backers, will accelerate the firm's mission to transform academic discoveries into viable companies. This initiative is poised to significantly enhance the translation of breakthrough science emerging primarily from the Yale University ecosystem.
A Foundation of Veteran Leadership
The firm is led by a team of seasoned biotech veterans, including Ranjit Bindra, Seth Herzon, Kevin Rakin, and Mike Dillon. Their collective experience is highlighted by the recent successful sale of Modifi Bio to Merck for up to $1.3 billion. This track record demonstrates their proficiency in navigating the complex journey from laboratory innovation to major strategic exits.
Bindra and Rakin alone have a collaborative history spanning over two decades, founding or investing in more than a dozen local biotech firms. Their efforts have been instrumental in attracting over $1 billion in capital to the New Haven area's life sciences sector. This deep-rooted experience provides CapeHaven with a unique advantage in identifying and nurturing high-potential scientific concepts.
Fueling Innovation and Expansion
This initial capital infusion is earmarked for several key strategic initiatives designed to bolster the company's operational capacity. The funds will support the expansion of CapeHaven's scientific and venture creation teams, enabling more robust evaluation of new opportunities. A primary focus will be advancing early-stage therapeutic concepts originating from academic research laboratories.
A significant portion of the funding will directly support the launch of Brainstorm Cancer Therapeutics, a new oncology-focused discovery company. This venture represents the first major project to be launched under the CapeHaven platform with this new capital. The investment ensures the firm can actively pursue and develop promising therapeutic programs from their earliest stages.
Strengthening the Yale Biotech Corridor
CapeHaven's model is designed to bridge the critical gap between academic discovery and the formation of a fundable commercial entity. The firm works in close partnership with scientific founders to develop their ideas through strategic planning and focused scientific development. This hands-on approach is intended to create capital-efficient companies positioned for long-term success and translational impact.
The initiative has received strong support from the local academic community, including Yale Ventures. Josh Geballe, its Managing Director, noted the value of having an experienced team dedicated to guiding laboratory innovations toward company creation. CapeHaven's blend of scientific, operational, and entrepreneurial expertise is seen as a vital catalyst for the regional ecosystem.
The successful first close of its funding round marks a significant milestone for CapeHaven and the New Haven biotech community. By leveraging its founders' extensive experience and strong ties to Yale, the firm is well-positioned to accelerate therapeutic innovation. This strategic investment will undoubtedly foster the creation of new companies and advance promising treatments from the lab to the clinic.